Significant Mismatch between FDG Uptake and Size after Chemotherapy in a Patient with Non-small Cell Lung Cancer.
- Author:
Seong Young KWON
1
;
Shin Young JEONG
;
Young Soon SEO
;
Jung Min HA
;
Ari CHONG
;
Jong Ryool OH
;
Ho Chun SONG
;
Jung Joon MIN
;
Hee Seung BOM
Author Information
1. Department of Nuclear Medicine, Chonnam National University Medical School, Gwangju, Korea. jjmin@chonnam.ac.kr
- Publication Type:Case Report
- Keywords:
Non-small cell lung cancer;
mismatch;
FDG;
size
- MeSH:
Aged;
Carcinoma, Non-Small-Cell Lung;
Follow-Up Studies;
Humans;
Lymph Nodes;
Neoplasm Metastasis;
Prognosis
- From:Nuclear Medicine and Molecular Imaging
2008;42(6):488-490
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A 75-year-old man with non-small cell lung cancer (NSCLC) underwent F-18 fluorodeoxyglucose (FDG) PET/CT for staging. PET/CT showed distant metastases to intra-abdominal lymph nodes (LNs) as well as bilateral mediastinal LNs (stage IV). He underwent PET/CT (restaging PET/CT) 1 week after the completion of first-line chemotherapy (docetaxel + carboplatin). It showed markedly increased FDG uptake in primary tumor, whereas tumor size decreased significantly, compared to prior PET/CT. This lesion was aggravated on follow-up CT 3 months after the completion of chemotherapy. Although there are several reports that FDG PET has potential to evaluate early response to chemotherapy and prognosis, there are a few cases to show mismatch between FDG uptake and size on PET/CT. Thus we report a case of NSCLC showed increased FDG uptake of primary tumor while decreased tumor size on restaging PET/CT.
